Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin)

Insights

Administering trivalent live, oral polio vaccine to neonates at 3 days of age effectively induces poliovirus immunity. Early infant immunization with oral polio vaccine establishes robust antibody levels and broad protection against poliovirus.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Neonatal immunization is crucial for early protection against infectious diseases.
  • Polio remains a significant public health concern, necessitating effective vaccination strategies.
  • Understanding the immunological response in neonates to oral polio vaccine is vital for optimizing immunization schedules.

Purpose of the Study:

  • To evaluate the immunological effects of administering trivalent live, oral polio vaccine to healthy neonates.
  • To determine the antibody response and seroconversion rates following different doses of oral polio vaccine in neonates.
  • To assess poliovirus excretion in neonates post-vaccination.

Main Methods:

  • A cohort of 200 healthy neonates in Henan Province, China, received trivalent live, oral polio vaccine.
  • Vaccination commenced at 3 days of age, with subsequent doses administered.
  • Antibody levels, geometric mean titres, and poliovirus excretion were monitored at various time points.
  • A control group received their initial vaccine dose at 2 months of age for comparison.

Main Results:

  • Antibody detection rates increased significantly after each dose, reaching nearly 100% after the fourth dose.
  • High geometric mean titres were observed for all three poliovirus types post-vaccination.
  • Poliovirus excretion was common after initial doses, increasing to 99% after the second dose.
  • Neonatal immunization induced immunity at the earliest possible age, comparable to controls vaccinated later.

Conclusions:

  • Early administration of oral polio vaccine to neonates is immunologically effective.
  • Neonatal immunization with oral polio vaccine induces protective antibody levels at a very young age.
  • This strategy offers the potential for earlier protection against poliomyelitis in infants.

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...